UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study

Arthritis research & therapy, 2022-08, Vol.24 (1), p.1-12, Article 208

2022

Volltextzugriff (PDF)

A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12‐Month Findings

ACR open rheumatology, 2023-08, Vol.5 (8), p.407-418

2023

Volltextzugriff (PDF)

Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR)

Journal of rheumatology, 2021-05, Vol.48 (5), p.767-774

2021

Volltextzugriff (PDF)

A Randomized, Placebo‐Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings

Arthritis & rheumatology (Hoboken, N.J.), 2023-02, Vol.75 (2), p.293-304

2023

Volltextzugriff (PDF)

Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis

Journal of rheumatology, 2006-02, Vol.33 (2), p.234

2006

Volltextzugriff (PDF)

Biosimilars and the extrapolation of indications for inflammatory conditions

Biologics, 2017-01, Vol.11, p.5-11

2017

Volltextzugriff (PDF)

Evolving treatment paradigms for rheumatoid arthritis: Translating comprehensive patient evaluations into personalized therapy

Seminars in arthritis and rheumatism, 2020-12, Vol.50 (6), p.1549-1549

2020

Volltextzugriff (PDF)

Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase

Annals of the rheumatic diseases, 2014-12, Vol.73 (12), p.2174-2177

2014

Volltextzugriff (PDF)

A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis

The New England journal of medicine, 2000-11, Vol.343 (22), p.1586-1593

2000

Volltextzugriff (PDF)

The evolution of biomarkers in rheumatoid arthritis: From clinical research to clinical care

Expert opinion on biological therapy, 2008-11, Vol.8 (11), p.1773-1785

2008

Volltextzugriff (PDF)

Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomes

Arthritis and rheumatism, 2002-06, Vol.46 (6), p.1443-1450

2002

Volltextzugriff (PDF)

Tramadol for the treatment of joint pain associated with osteoarthritis: a randomized, double-blind, placebo-controlled trial

Current therapeutic research, 2001-02, Vol.62 (2), p.113-128

2001

Volltextzugriff (PDF)

Use of antipolymer antibody assay in recipients of silicone breast implants

The Lancet (British edition), 1997-02, Vol.349 (9050), p.449-454

1997

Volltextzugriff (PDF)

An autopsy study of the prevalence of monosodium urate and calcium pyrophosphate dihydrate crystal deposition in first metatarsophalangeal joints

Arthritis and rheumatism, 1983-12, Vol.26 (12), p.1522-1524

1983

Volltextzugriff (PDF)

Chronic liver disease and still's disease

Arthritis and rheumatism, 1982-05, Vol.25 (5), p.579-582

1982

Volltextzugriff (PDF)

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

The New England journal of medicine, 2015-10, Vol.373 (14), p.1329-1339

2015

Volltextzugriff (PDF)

Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT)

Journal of rheumatology, 2024-07, Vol.51 (7), p.663-672

2024

Volltextzugriff (PDF)

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

Rheumatology and therapy., 2023-12, Vol.10 (6), p.1479-1501

2023

Volltextzugriff (PDF)

Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

ACR open rheumatology, 2024-05, Vol.6 (5), p.304-311

2024

Volltextzugriff (PDF)

Baseline Renal Characteristics and Trial Design for MIRROR RCT, Randomized Trial of Pegloticase with or Without Methotrexate for Uncontrolled Gout: PUB314

Journal of the American Society of Nephrology, 2021-10, Vol.32 (10S), p.852-852

2021

Volltextzugriff (PDF)

Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis

The New England journal of medicine, 1995-07, Vol.333 (3), p.137-142

1995

Volltextzugriff (PDF)

Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis

Journal of rheumatology, 2004-04, Vol.31 (4), p.649

2004

Volltextzugriff (PDF)

CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis

Journal of rheumatology, 2002-02, Vol.29 (2), p.220

2002

Volltextzugriff (PDF)

Antipolymer antibody reactivity in a subset of patients with fibromyalgia correlates with severity

Journal of rheumatology, 1999-02, Vol.26 (2), p.402

1999

Volltextzugriff (PDF)

Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis

Arthritis research, 2001-01, Vol.3 (4), p.247-252, Article 247

2001

Volltextzugriff (PDF)

1 – 25 von 30

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(24)
Mit Volltextzugriff
(23)

Publikationsform

Artikel
(30)

Sprache

Englisch
(30)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(27)
Science & Technology
(27)
Rheumatology
(22)
Humans
(18)
Biological And Medical Sciences
(14)
Female
(14)
Male
(13)
Medical Sciences
(13)
Middle Aged
(13)
Adult
(11)
Treatment Outcome
(11)
Aged
(9)
Rheumatoid Arthritis
(9)
Arthritis, Rheumatoid - Drug Therapy
(8)
Double-Blind Method
(8)
Pharmacology. Drug Treatments
(7)
Methotrexate
(6)
Patients
(6)
Severity Of Illness Index
(6)
Antirheumatic Agents - Adverse Effects
(5)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study

A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12‐Month Findings

Pegloticase in Combination With Methotrexate in Patients With Uncontrolled Gout: A Multicenter, Open-label Study (MIRROR)

A Randomized, Placebo‐Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings

Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis

Biosimilars and the extrapolation of indications for inflammatory conditions

Evolving treatment paradigms for rheumatoid arthritis: Translating comprehensive patient evaluations into personalized therapy

Rheumatoid arthritis secondary non-responders to TNF can attain an efficacious and safe response by switching to certolizumab pegol: a phase IV, randomised, multicentre, double-blind, 12-week study, followed by a 12-week open-label phase

A Comparison of Etanercept and Methotrexate in Patients with Early Rheumatoid Arthritis

The evolution of biomarkers in rheumatoid arthritis: From clinical research to clinical care

Etanercept versus methotrexate in patients with early rheumatoid arthritis: Two‐year radiographic and clinical outcomes

Tramadol for the treatment of joint pain associated with osteoarthritis: a randomized, double-blind, placebo-controlled trial

Use of antipolymer antibody assay in recipients of silicone breast implants

An autopsy study of the prevalence of monosodium urate and calcium pyrophosphate dihydrate crystal deposition in first metatarsophalangeal joints

Chronic liver disease and still's disease

Secukinumab Inhibition of Interleukin-17A in Patients with Psoriatic Arthritis

Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT)

Six-Month Persistence and Multi-domain Effectiveness of Guselkumab in Adults with Psoriatic Arthritis: Real-World Data from the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

Improvements in Patient-Reported Outcomes Through Six Months of Guselkumab Treatment in Patients With Active Psoriatic Arthritis: Real-World Data From the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry

Baseline Renal Characteristics and Trial Design for MIRROR RCT, Randomized Trial of Pegloticase with or Without Methotrexate for Uncontrolled Gout: PUB314

Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis

Concomitant medication use in a large, international, multicenter, placebo controlled trial of anakinra, a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis

CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis

Antipolymer antibody reactivity in a subset of patients with fibromyalgia correlates with severity

Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis

Suchergebnisse filtern